Propionic Acidemia Treatment Pipeline 2023: FDA Approvals, Clinical Trials, Therapeutic Insights, Mechanism of Action, and Administration Routes by DelveInsight | VectivBio, Agios Pharmaceuticals

Propionic Acidemia Treatment Pipeline 2023: FDA Approvals, Clinical Trials, Therapeutic Insights, Mechanism of Action, and Administration Routes by DelveInsight | VectivBio, Agios Pharmaceuticals
Propionic Acidemia Pipeline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Propionic Acidemia pipeline constitutes 5+ key companies continuously working towards developing 5+ Propionic Acidemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Propionic Acidemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Propionic Acidemia Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Propionic Acidemia Market.


Some of the key takeaways from the Propionic Acidemia Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Propionic Acidemia treatment therapies with a considerable amount of success over the years. 
  • Propionic Acidemia companies working in the treatment market are VectivBio, Agios Pharmaceuticals, BridgeBio, HemoShear Therapeutics, and others, are developing therapies for the Propionic Acidemia treatment 
  • Emerging Propionic Acidemia therapies in the different phases of clinical trials are- VB-1197, BCAT2 inhibitors, BBP-671, HST 5040, and others are expected to have a significant impact on the Propionic Acidemia market in the coming years. 
  • In July 2022, In patients with propionic or methylmalonic acidemia, HemoShear Therapeutics began a Phase II open-label, dose-escalation trial of HST5040. This was followed by a randomised, double-blind, placebo-controlled, 2-period crossover study and an open-label, long-term extension study.  


Propionic Acidemia Overview

Propionic acidemia is an uncommon metabolic condition that affects anywhere between 1/20,000 and 1/250,000 people worldwide. Propionyl-CoA carboxylase, an enzyme involved in the breakdown (catabolism) of the chemical “building blocks” of proteins (amino acids), is deficient in this condition.


Get a Free Sample PDF Report to know more about Propionic Acidemia Pipeline Therapeutic Assessment-


Emerging Propionic Acidemia Drugs Under Different Phases of Clinical Development Include:

  • VB-1197: VectivBio
  • BCAT2 inhibitors: Agios Pharmaceuticals
  • BBP-671: BridgeBio
  • HST 5040: HemoShear Therapeutics


Propionic Acidemia Route of Administration

Propionic Acidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical


Propionic Acidemia Molecule Type

Propionic Acidemia Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 


Propionic Acidemia Pipeline Therapeutics Assessment

  • Propionic Acidemia Assessment by Product Type
  • Propionic Acidemia By Stage and Product Type
  • Propionic Acidemia Assessment by Route of Administration
  • Propionic Acidemia By Stage and Route of Administration
  • Propionic Acidemia Assessment by Molecule Type
  • Propionic Acidemia by Stage and Molecule Type


DelveInsight’s Propionic Acidemia Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Further Propionic Acidemia product details are provided in the report. Download the Propionic Acidemia pipeline report to learn more about the emerging Propionic Acidemia therapies


Some of the key companies in the Propionic Acidemia Therapeutics Market include:

Key companies developing therapies for Propionic Acidemia are – Moderna, HemoShear Therapeutics, CoA Therapeutics, Inc., Agios Pharmaceuticals, Imbria Pharmaceuticals, Comet Therapeutics, and others.


Propionic Acidemia Pipeline Analysis:

The Propionic Acidemia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Propionic Acidemia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Propionic Acidemia Treatment.
  • Propionic Acidemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Propionic Acidemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Propionic Acidemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Propionic Acidemia drugs and therapies


Propionic Acidemia Pipeline Market Drivers

  • Increasing awareness regarding propionic acidemia, increasing geriatric population, improvement in treatment and R&D are some of the important factors that are fueling the Propionic Acidemia Market.


Propionic Acidemia Pipeline Market Barriers

  • However, lack of Awareness about the treatments, No targeted pharmacologic treatments for Propionic Acidemia and other factors are creating obstacles in the Propionic Acidemia Market growth.


Scope of Propionic Acidemia Pipeline Drug Insight    

  • Coverage: Global
  • Key Propionic Acidemia Companies: VectivBio, Agios Pharmaceuticals, BridgeBio, HemoShear Therapeutics, and others
  • Key Propionic Acidemia Therapies: VB-1197, BCAT2 inhibitors, BBP-671, HST 5040, and others
  • Propionic Acidemia Therapeutic Assessment: Propionic Acidemia current marketed and Propionic Acidemia emerging therapies
  • Propionic Acidemia Market Dynamics: Propionic Acidemia market drivers and Propionic Acidemia market barriers 


Request for Sample PDF Report for Propionic Acidemia Pipeline Assessment and clinical trials


Table of Contents 

1. Propionic Acidemia Report Introduction

2. Propionic Acidemia Executive Summary

3. Propionic Acidemia Overview

4. Propionic Acidemia- Analytical Perspective In-depth Commercial Assessment

5. Propionic Acidemia Pipeline Therapeutics

6. Propionic Acidemia Late Stage Products (Phase II/III)

7. Propionic Acidemia Mid Stage Products (Phase II)

8. Propionic Acidemia Early Stage Products (Phase I)

9. Propionic Acidemia Preclinical Stage Products

10. Propionic Acidemia Therapeutics Assessment

11. Propionic Acidemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Propionic Acidemia Key Companies

14. Propionic Acidemia Key Products

15. Propionic Acidemia Unmet Needs

16 . Propionic Acidemia Market Drivers and Barriers

17. Propionic Acidemia Future Perspectives and Conclusion

18. Propionic Acidemia Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States